Verigene® gram-positive blood culture nucleic acid test: An in vitro diagnostic assay for identification of gram-positive bacteria associated with bloodstream infections and bacterial resistance markers

Molecular Diagnosis and Therapy

Volumn 17, Issue 2, 2013, Pages 117-122

  Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; PENICILLIN BINDING PROTEIN 2A; UNCLASSIFIED DRUG; VANA PROTEIN; VANB PROTEIN;

ANTIBIOTIC RESISTANCE; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BLOOD CULTURE; BLOODSTREAM INFECTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; LIMIT OF DETECTION; LISTERIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR DIAGNOSIS; NONHUMAN; NUCLEIC ACID ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS; TECHNOLOGY;

BACTEREMIA; ENTEROCOCCUS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; STAPHYLOCOCCUS; STREPTOCOCCUS;

EID: 84877359495     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-013-0021-z     Document Type: Review

References (20)

1. Paolucci M, Landini MP, Sambri V. Conventional and molecular techniques for the early diagnosis of bacteraemia. Int J Antimicrob Agents. 2010;36(Suppl 2):S6-16.
2. Wenzel RP, Edmond MB. The impact of hospital-acquired bloodstream infections. Emerging Infect Dis. 2001;7(2):174-7. (Pubitemid 32374322)
3. Bauer M, Reinhart K. Molecular diagnostics of sepsis: where are we today? Int J Med Microbiol. 2010;300(6):411-3.
4. Kost GJ, Tran NK, Louie RF, et al. Rapid diagnosis of sepsis: point-of-care testing, nucleic acid testing, and the value model. Point Care. 2003;2(3):163-71.
5. Lehmann LE, Herpichboehm B, Kost GJ, et al. Cost and mortality prediction using polymerase chain reaction pathogen detection in sepsis: evidence from three observational trials. Critical Care. 2010;14:R186.
6. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589-96. (Pubitemid 43810035)
7. Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009;136(5):1237-48.
8. Huttunen R, Aittoniemi J. New concepts in the pathogenesis, diagnosis and treatment of bacteremia and sepsis. J Infect. 2011;63(6):407-19.
9. Septimus EJ, Kuper KM. Clinical challenges in addressing resistance to antimicrobial drugs in the twenty-first century. Clin Pharmacol Ther. 2009;86(3):336-9.
10. Gandhi TN, DePestel DD, Collins CD, et al. Managing antimicrobial resistance in intensive care units. Crit Care Med. 2010;38(8):S315-23.
11. Wallet F, Nseir S, Baumann L, et al. Preliminary clinical study using a multiplex real-time PCR test for the detection of bacterial and fungal DNA directly in blood. Clin Microbiol Infect. 2010;16(6):774-9.
12. Alahmadi YM, Aldeyab MA, McElnay JC, et al. Clinical and economic impact of contaminated blood cultures within the hospital setting. J Hosp Infect. 2011;77(3):233-6.
13. Dellinger RP, Levy MM, Carlet JM. Surviving Sepsis Campaign: international guidelines for the management of severe sepsis and septic shock 2008 (published erratum appears in Intensive Care Med 2008;36(4):1394-6). Intensive Care Med. 2008;36(1):296-327.
14. Zwang O, Albert RK. Analysis of strategies to improve cost effectiveness of blood cultures. J Hosp Med. 2006;1(5):272-6.
15. US FDA. Clinical Laboratory Improvement Amendments (CLIA). http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ IVDRegulatoryAssistance/ucm124105.htm. Accessed 29 Nov 2012.
16. US FDA. Evaluation of automatic Class III designation (de novo) for Verigene® Gram-Positive Blood Culture Nucleic Acid Test (BC-GP). http://www.accessdata.fda.gov/cdrh-docs/reviews/K113450.pdf. Accessed 8 Oct 2012.
17. Buchan BW, Mackey T-L, Cahak C, et al. Rapid detection of Gram-positive bacteria and resistance determinants directly from positive blood cultures using the microarray-based sample-to-result Verigene BC-GP assay (poster no. P-1700). In: 22nd European Congress of Clinical Microbiology and Infectious Diseases, London, 31 Mar-3 Apr 2012.
18. Tormo N, Medina R, Ocete MD, et al. Performance of the nanosphere's Verigene BC-GP test for rapid detection of Gram-positive bacteria and resistance determinants directly from positive blood cultures (poster). In: 22nd European Congress of Clinical Microbiology and Infectious Diseases, London, 31 Mar-3 Apr 2012.
19. Buchan BW, Mackey T, Cahak C, et al. Evaluation of the microarray-based sample-to-result Verigene BC-GP assay for rapid detection of Gram-positive bacteria and resistance determinants directly from positive blood cultures (abstract). In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 17-20 Sep 2011.
20. Anderson C, Kaul K, Voss B, et al. Evaluation of the Verigene Gram-positive blood culture test (BC-GP) (poster no. 1163). In: 112th American Society for Microbiology General Meeting, San Francisco, 16-19 Jun 2012.